30 results about "Degenerative disc" patented technology

The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc through an aperture or incision. If the aperture or incision is closed with a suture or a glue after introduction of the chondrocytes, the closure can withstand over 400 N of compression force.

The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc.

In the repair / regenerate of the intervertebral disc, all or a portion of the nucleus pulposus or annulus fibrosus is excised and treated for reinsertion into the disc or adjacent or alternate level disc. Alternatively certain bioactive agents may be injected into the degenerative disc without excising disc material.

Disclosed are a mixed porous structure interbody fusion cage and a preparation method thereof. The interbody fusion cage comprises a porous metal support and porous structure filling bodies, the porous metal support is a three-dimensional net-shaped structure, a plurality of holes are arranged in the porous metal support, and the porous structure filling bodies are fully filled in the holes. The preparation method includes steps that the metal rapid forming technology is directly combined with the freeze drying technology, the porous metal support is manufactured via a structural design and the direct metal rapid forming technology, then uniformly mixed polymer gel or polymer / biological ceramic compound gel is poured in the porous metal support to realize freeze treatment, so that the porous structure filling bodies with the micropore feature are formed after freeze drying, and the mixed porous structure interbody fusion cage is obtained. Mechanical compatibility is good, contact area between the mixed porous structure interbody fusion cage and natural centrum is further increased, instant stability is good, fusion rate is improved, and the mixed porous structure interbody fusion cage and the preparation method thereof can be used for treating clinical degenerative disc diseases.

The present invention provides seating apparatuses that may reduce an effect of an ailment such as sciatica, joint illness, degenerative disc condition, hip bursitis, tendinitis, or sacral / coccyx pain. A seating apparatus includes a back portion and a seating portion, each portion having at least one encased bladder that is inflated by a pumping component in a timed sequence. The bladders may be differently shaped, asymmetrically situated with respect to a center axis, and spatially overlapping. The bladders are inflated and deflated in accordance with a predetermined time sequence and are independently controlled. The seating apparatus may contain a set of encased bladders that may be configured for different aliments. A user selects a treatment for one of the ailments through a remote control unit. Consequently, a subset of bladders is configured so that the selected subset of bladders is inflated and deflated.

The present invention provides novel block copolymers as structural supplements for injectible bodily prosthetics employed in medical or cosmetic procedures. The invention also includes the use of such block copolymers as nucleus pulposus replacement materials for the treatment of degenerative disc disorders and spinal injuries. The copolymers are constructed by polymerization of a tertiary amine methacrylate with either a (poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) polymer, such as the commercially available Pluronic® polymers, or a poly(ethylene glycol) methyl ether polymer.

Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also comprise one or more binders. The device can be an elongate solid body having a tapered or rounded insertion end. Alternatively, the device can include a plurality of particles. For devices containing multiple active agents, the configuration of the device be chosen to provide for the sequential or simultaneous release of each of the active agents. The elongate solid body can include a sheath comprising a first active agent and a core comprising a second active agent.

A power tool for removing an intervertebral disc and preparing vertebral endplates is described. The power tool may include a cutting element, and the height of the cutting element may be adjustable. The cutting element may be a braided cable and may include one or more beads to enhance the effectiveness of the cable. The cutting element may have a minimum height requirement, which may not be satisfied in patients with a collapsed disc due to degenerative disc disorder. For these patients, also described are bone tamps for increasing the intervertebral distance and providing access to tissues distal to the tamp. One type of bone tamp features an inflatable balloon with an inner lumen. Another type of bone tamp includes an expanding distal end and an inner cannula. Also described is a manual expander scraper tool that is compatible with both types of bone tamp.

Methods for treating degenerative disc disease by administering a human birth tissue material composition are provided. The method includes the step of administering a human birth tissue material composition onto or into at least one intervertebral disc or intervertebral space in need of treatment.

The present invention provides a disc restoration system for relieving symptoms of a degenerative disc, comprising: a) a percutaneously insertable expandable element (88) adapted to be (i) inserted in between two adjacent vertebraes of the spinal cord; and, (ii) expanded to form a scaffold; said scaffold provides mechanical support to said two adjacent vertebraes so as to restore said degenerative disc to approximately the dimensions of a normal disc; b) an injectable filler having a first flowable state, and a second non-flowable set state; the filler is configured for being introduced, in said first flowable state, into a confined volume formed by the expandable element and the tissues, following the full expansion of said expandable element in said disc; and, following introduction of said filler, said filler is adapted to set into said second non-flowable state; such that following setting of said filler into said second state said disc is internally supported by said set filler.

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).

Systems, methods and computer program products for facilitating the prognosis of degenerative disc disorder (DDD) are provided. In one aspect, intervertebral disc loss is predicted based on receiving image data comprising one or more images of the human spine; segmenting, using a processor, disc regions of said one or more images; generating, using the processor, individual biomarkers based on texture features of said segmented disc regions; generating, using the processor, a predicting intervertebral disc loss based in part on the prognostic marker generated from the individual biomarkers.

Embodiments of the disclosure include methods and compositions related to preparation of fibroblasts for use of treatment and prevention of a degenerative disc in an individual. In particular cases, fibroblasts are subject to de-differentiation that results in enhancement of their therapeutic activity and such methods include exposure of the fibroblasts to one or more agents and / or conditions.

Systems, methods and computer program products for facilitating the prognosis of degenerative disc disorder (DDD) are provided. In one aspect, intervertebral disc loss is predicted based on receiving image data comprising one or more images of the human spine; segmenting, using a processor, disc regions of said one or more images; generating, using the processor, individual biomarkers based on texture features of said segmented disc regions; generating, using the processor, a predicting intervertebral disc loss based in part on the prognostic marker generated from the individual biomarkers.

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material (6) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material (10) that is dry and can be stored at room temperature for long periods of time. This powder (10) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture (20).

The invention relates to the technical field of lumbar intervertebral disc medical treatment, in particular to a preparation for treating degenerative disc diseases and a preparation method. The preparation for treating the degenerative disc diseases comprises mesenchymal stem cells, and the mesenchymal stem cells are induced and cultured by a conditional culture medium of chondrocytes, so that the differentiation of the mesenchymal stem cells is facilitated; and the mesenchymal stem cells are wrapped with hydrogel, and the survival rate and activity of the mesenchymal stem cells in the body are enhanced. The invention also provides a heat preservation injector used for the preparation for treating degenerative disc diseases, and the tube wall of the heat preservation injector is filled with a heat preservation material, so that the temperature of contents is ensured, the activity of cells is favorably maintained, and the stress reaction of an organism is reduced.

Effective treatments of pain and / or inflammation from degenerative disc disease and / or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and / or facet joint, one can reduce, prevent or treat pain and / or inflammation caused by the degenerative disc disease and / or facet joint.

Effective treatments of pain and / or inflammation from degenerative disc disease and / or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and / or facet joint, one can reduce, prevent or treat pain and / or inflammation caused by the degenerative disc disease and / or facet joint.

The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1 and a pharmaceutically acceptable salt thereof effective for treating degenerative disc diseases, treating body organ fibrosis, treating cancer and / or treating glomerulosclerosis, and effective for the inhibition of TGF-beta 1 signaling.

The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1, a variant thereof and a pharmaceutically acceptable salt thereof.A novel peptide of the present invention, a variant thereof and a pharmaceutically acceptable salt thereof are effective for treating and / or preventing degenerative disc diseases, treating body organ fibrosis, treating cancer and / or treating glomerulosclerosis, and are effective for the inhibition of TGF-beta1 signaling.